EA202192532A1 - Мирикизумаб для применения в способе лечения болезни крона - Google Patents

Мирикизумаб для применения в способе лечения болезни крона

Info

Publication number
EA202192532A1
EA202192532A1 EA202192532A EA202192532A EA202192532A1 EA 202192532 A1 EA202192532 A1 EA 202192532A1 EA 202192532 A EA202192532 A EA 202192532A EA 202192532 A EA202192532 A EA 202192532A EA 202192532 A1 EA202192532 A1 EA 202192532A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
treatment
crohn
mirikizumab
antibody
Prior art date
Application number
EA202192532A
Other languages
English (en)
Russian (ru)
Inventor
Стюарт Уильям Фридрих
Пол Фредерик Поллак
Джей Лоуренс Таттл
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202192532A1 publication Critical patent/EA202192532A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
EA202192532A 2019-04-22 2020-04-15 Мирикизумаб для применения в способе лечения болезни крона EA202192532A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (1)

Publication Number Publication Date
EA202192532A1 true EA202192532A1 (ru) 2022-01-21

Family

ID=70554215

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192532A EA202192532A1 (ru) 2019-04-22 2020-04-15 Мирикизумаб для применения в способе лечения болезни крона

Country Status (21)

Country Link
US (1) US20220040299A1 (enExample)
EP (3) EP3958897B1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
DK (1) DK3958897T3 (enExample)
EA (1) EA202192532A1 (enExample)
ES (1) ES3075314T3 (enExample)
FI (1) FI3958897T3 (enExample)
IL (2) IL286818B2 (enExample)
LT (1) LT3958897T (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
PT (1) PT3958897T (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20160031983A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
EP3652539A4 (en) * 2017-07-10 2021-03-31 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODIES IN ORGANIC MEDICINE TREATED PATIENTS AND USES THEREOF IN PERSONALIZED MEDICINE
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
CN113677366A (zh) 2021-11-19
BR112021018930A2 (pt) 2022-01-18
EP3958897A1 (en) 2022-03-02
JP7761614B2 (ja) 2025-10-28
ZA202108094B (en) 2025-05-28
TW202515610A (zh) 2025-04-16
AU2020263238B2 (en) 2023-08-17
AU2020263238C1 (en) 2024-02-22
WO2020219314A1 (en) 2020-10-29
EP4778573A2 (en) 2026-07-22
TWI850365B (zh) 2024-08-01
CN119700968A (zh) 2025-03-28
EP3958897B1 (en) 2026-05-06
PT3958897T (pt) 2026-07-17
KR20250153865A (ko) 2025-10-27
AU2020263238A1 (en) 2021-11-04
SG11202110619XA (en) 2021-11-29
IL286818A (en) 2021-10-31
JP2025148449A (ja) 2025-10-07
EP4789714A2 (en) 2026-08-12
UA128657C2 (uk) 2024-09-18
KR102869852B1 (ko) 2025-10-14
NZ781127A (en) 2025-06-27
MX2021012848A (es) 2021-12-10
DK3958897T3 (da) 2026-07-20
JP7297930B2 (ja) 2023-06-26
US20220040299A1 (en) 2022-02-10
TW202103734A (zh) 2021-02-01
LT3958897T (lt) 2026-08-10
AU2023265759A1 (en) 2023-12-07
JP2023116680A (ja) 2023-08-22
ES3075314T3 (en) 2026-08-03
FI3958897T3 (fi) 2026-07-16
IL286818B1 (en) 2025-11-01
KR20210142704A (ko) 2021-11-25
MA55756A (fr) 2022-03-02
IL286818B2 (en) 2026-03-01
JP2022530397A (ja) 2022-06-29
CA3134587A1 (en) 2020-10-29
IL324048A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
MA52216B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
CO2019012353A2 (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
WO2018075692A3 (en) Antibody constructs
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
EA201991736A1 (ru) Антитело против оболочечного herv-k и его применение
CO2018000414A2 (es) Inmunoconjugados de il22
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
MX380557B (es) Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
EA201992883A1 (ru) АНТИТЕЛА К TrkB
EP3947466A4 (en) ANTI-HLA-DQ2.5 ANTIBODIES
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.
EA202190504A1 (ru) Способы лечения псориаза
EA201990768A1 (ru) Оптимизированные синтетические консенсусные иммуногенные композиции, нацеленные на белок активации фибробластов